Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Euronext Paris  -  11:35 2022-08-19 am EDT
1.279 EUR   -0.43%
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

France's Novacyt Rolls Out Monkeypox Assay

06/28/2022 | 03:03am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about NOVACYT
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-P..
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
07/28Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay
CI
07/21NOVACYT : Results of Annual General Meeting
PU
07/21NOVACYT : AGM Investor Presentation
PU
07/15Novacyt - Approval of exsig COVID-19 Direct test in the UK under CTDA legislation
AQ
07/15UK Watchdog OKs Novacyt's exsig COVID-19 Direct Test
MT
07/15Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK
CI
07/07NOVACYT : Half-year results
CO
More news
Financials
Sales 2021 95,8 M - -
Net income 2021 -9,73 M - -
Net cash 2021 99,9 M - -
P/E ratio 2021 -31,3x
Yield 2021 -
Capitalization 90,7 M 91,0 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,19x
Nbr of Employees 276
Free-Float 94,8%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Paul Oladimeji Group Head-Research & Development
Bryan Close Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-70.68%92
GILEAD SCIENCES, INC.-10.23%81 694
VERTEX PHARMACEUTICALS34.01%75 473
REGENERON PHARMACEUTICALS, INC.-1.06%66 800
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689